4,898 transcripts
Page 22 of 100
bu8
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
that the information discussed today is qualified in its entirety by the Form 8-K filed today by PLBY Group, which may be accessed on the SEC's website and PLBY
zbas
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
of the company's website, ir.evolent.com. And the Form 8-K filed by the company with the SEC earlier today. In addition to reconciliations, we provide details
nt
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
Forms 10-K and 10-Q, which identify risks that may cause future actual results or events to differ materially. OncoCyte expressly disclaims any intent
i7p3
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
profile. The 8-K that we filed this morning on the transaction actually walk through the deal economics, so maybe I'll just start there. So
qktp
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
and uncertainties are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q, that has been filed with the SEC. We
5u
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
shareholder letter on the Investor Relations section of our website and furnished it on an 8-K. You can also find these materials at the SEC free of charge
c17
Earnings call transcript
NYSE
2025 Q1
8 Aug 24
from those expressed on the call. A discussion of these risks and uncertainties is included in our annual report on Form 10-K and other SEC filings. We
lmh
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
this conference call, we furnished our second quarter 2024 earnings press release with the SEC on Form 8-K and have posted along with supplemental financial
55h
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
Good afternoon. I'd like to welcome everyone to REPAY's Second Quarter 2024 Earnings Conference Call. This call is being recorded today, August 8
ph4m
Earnings call transcript
NASDAQ
2024 Q4
8 Aug 24
recent 8-K filing made today and our most recent 10-Q filing. Forward-looking statements are based on assumptions as of today and the company undertakes
ez2
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
. We identify the principal risks and uncertainties that affect our performance in our annual report on Form 10-K and other SEC filings.
With that, I
73ha
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
annual report on Form 10-K. These forward-looking statements are based on assumptions as of today, August 5, 2024, and Veritone undertakes no obligation
0d3
Earnings call transcript
NASDAQ
2025 Q1
8 Aug 24
refer to the risk factors described in AMMO's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today
864
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
in our annual report on Form 10-K for the fiscal year ended December 31, 2020, as well as other public reports filed with the SEC.
Finally
he
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
, as described in our 8-K at the end of July.
Our share count across our Class A and V common stock was 152 million as of August 4, 2024.
A reconciliation
el
Earnings call transcript
NASDAQ
2024 Q3
8 Aug 24
current report on Form 8-K describe the differences between our GAAP and non-GAAP reporting and present the reconciliation between the 2 for the periods
3c
Earnings call transcript
NYSE
2024 Q2
8 Aug 24
rate to an 8% cap rate. Also, as you'll note in the 8-K that was filed, the leverage percentage for the office side was at 50%, and we have a leverage
j7xs
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
in the company's most recent annual report from Form 10-K, subsequent quarterly reports on Form 10-Q and the recent press releases. These 3 is reports
94od
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
not place reliance on these statements.
For a discussion of the risks and uncertainties associated with our business, please see our most recent Form 10-K
s2a
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
in conventional T cells and K cells or monocytes.
NKTRO-165 also drove T-reg proliferation, upregulation of FOX P3 and other activation markers